Tissue Regenix Group PLC Notice of Preliminary Results (9305G)

TIDMTRX

RNS Number : 9305G

Tissue Regenix Group PLC

09 March 2015

Tissue Regenix Group plc

("Tissue Regenix" or "the Company")

Notice of Preliminary Results

YORK, 9(th) March 2015 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix"), the regenerative medical devices company, announces that it will publish its unaudited preliminary results for the year ended 31 January 2015, on Monday 11(th) May 2015.

For Further Information

 
 Tissue Regenix Group Plc: 
  Antony Odell 
  Ian Jefferson               +44 19 0443 5176 
 Jefferies International 
  Ltd: 
  Simon Hardy 
  Harry Nicholas              +44 20 7029 8000 
 Tulchan Communications: 
  Tom Buchanan 
  Victoria Huxster            +44 207 353 4200

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL(R) technology platform.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOREALDNEEASEFF

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024